Open access · CC-BY
via OpenAlex
GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension
Experimental Gerontology · 2026
Epigenetic alterations
Dysbiosis
Deregulated nutrient-sensing
Altered intercellular communication
Chronic inflammation
Human
Randomized controlled trial
Preclinical / animal
Review
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events, all-cause mortality, and systemic inflammation in randomized controlled trials, with effect sizes exceeding those predicted from glycemic and weight-related improvements alone. The convergence of these findings with a maturing body of evidence linking metabolic dysfunction to accelerated epigenetic aging has prompted renewed interest in GLP-1 RAs as candidate gerotherapeutic agents. The present review synthesizes contemporary preclinical, mechanistic, and clinical evidence relevant to this question. The SELECT trial demonstrated a 19% reduction in all-cause mortality (hazard ratio [HR] 0.81) in patients with obesity without diabetes, the FLOW trial demonstrated a 24% reduction in the primary kidney composite endpoint (HR 0.76), and the first randomized evidence of GLP-1 RA modulation of validated DNA methylation clocks was reported in 2025, with significant deceleration of DunedinPACE, PCGrimAge, and PhenoAge over 32 weeks of semaglutide therapy. Mechanistic studies have identified convergent pathways involving the hypothalamic GLP-1 receptor, AMPK/SIRT1 signaling, and microbiome-derived short-chain fatty acid production. The aggregate evidence supports the framing of GLP-1 RAs as a candidate class of geroprotective therapeutics, although definitive trials with prespecified epigenetic aging endpoints, durability follow-up, body-composition assessment, prespecified sex-stratified analyses, and adequate representation of diverse populations remain to be conducted; the pending EVOKE and EVOKE+ readouts in early Alzheimer's disease will be particularly consequential.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.exger.2026.113325
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Al‐Ali, D., & Hajj, N.E. (2026). GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension. <em>Experimental Gerontology</em>. https://doi.org/10.1016/j.exger.2026.113325
Vancouver
Al‐Ali D, Hajj NE. GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension. Experimental Gerontology. 2026. doi:10.1016/j.exger.2026.113325.
BibTeX
@article{dana2026GLPrec,
title = {GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension},
author = {Dana Al‐Ali and Nady El Hajj},
journal = {Experimental Gerontology},
year = {2026},
doi = {10.1016/j.exger.2026.113325},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
American Journal of Psychiatry 2018
Open access · OA
Epigenetic Aging in Major Depressive Disorder
medRxiv 2025
Preprint · CC-BY
Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial
Aging and Disease 2025
Open access · CC-BY
Epigenetic Clocks Identify Harmful Epigenetic Aging Linked to Depression Severity and Cognitive Deficits in Major Depressive Disorder
Nature Reviews Neurology 2025
Preprint · CC-BY
Epigenetic clocks and DNA methylation biomarkers of brain health and disease
2020
Citation only
Epigenetics and aging
Nutrients 2026
Citation only